Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Despite your quoted book cost they were free with your TILS shares.
But I can't deny it is annoying. I have nearly 20k of them.
And... breathe.
They've been trading for some weeks on the NASDAQ. I'm sure it's been mentioned here a few times.
Currently appear to be around the $.079 mark though fairly volatile.
Google "share price acut"
Google says it went up 40% on Monday
An annual report (or maybe a transition report, but I think it is the former) has been issued. I've not read it in depth but the bits which were on interest to me ( - some of which we already knew) were
- As of December 31, 2021, the Company had 1 full time employee
- Our principal capital expenditures are devoted to conducting research and development of our novel product candidate, StemPrintER, establishing US corporate headquarters with a Clinical Laboratory Improvement Amendments “CLIA”-certified laboratory and further validating the StemPrint platform in other tumor type
- We qualify as an “emerging growth company” as defined in the U.S. Jumpstart Our Business Startups Act of 2012
- The largest validation study for StemPrintER involved the retrospective analysis of nearly 2,400 breast tumor samples collected through the IEO clinical network. In this published study, StemPrint and StemPrintER were highly prognostic
- the recent independent validation using the TransATAC cohort demonstrates the immediate relevance of StemPrintER
- Our initial plan is to launch StemPrintER testing for patients with breast cancer once we have achieved several key milestones. First, we are planning to build corporate headquarters in Phoenix, AZ that will also house a clinical laboratory. [Further detail omitted here] Once those tasks are complete we will be able to commercially launch StemPrintER, and we plan to focus on the US market.
There are also some risks spelt out, including one I reported before here from an earlier document which goes
"We need substantial additional funding to complete the development of its product candidates, which may not be available on acceptable terms, if at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development, research operations or future commercialization efforts, if any"
There is much more detail in the doc, and they state more funding WIL be required to advance the product but the risk is the rather ominous "If we are unable to obtain adequate funding on a timely basis, we may be required to significantly curtail, delay or discontinue our R&D programs of our product candidates or any future commercialization efforts, be unable to expand our operations or be unable to otherwise capitalize on our business opportunities, as desired, which could harm our business and potentially cause a discontinuation of operation"
On the whole it's a quite good read and sets out the position reasonably clearly. Everyone invested should read it for themselves and form their own conclusion as to the appropriateness of their investment. It's here https://sec.report/Document/0001493152-22-010172/
As per my earlier post "This filing shows that Tiziana bought 1,337,970 shares in Accustem for $2 each on 30 March. This fulfilled the demerger undertaking, AIUI.
https://sec.report/Document/0001493152-22-009142/
I would say that is after the split although I don't remember exactly when the split was.
Cos they are trading on the proper NASDAQ not the pink market I believe
This filing shows that Tiziana bought 1,337,970 shares in Accustem for $2 each on 30 March. This fulfilled the demerger undertaking, AIUI.
https://sec.report/Document/0001493152-22-009142/
So a useful cash injection but it won't last forever and we could do with knowing more about what they are up to. I see the SP seems to have gone up 17%+ today.
Now $1.60 down nearly 6%
At it's simplest this obviously appears true but when you sell you are selling to a trader not to an investor, similar when buying. Price depends on supply and demand, so if there is more selling pressure than buying the price drops, again and vice versa.
I can't be bothered explaining myself further as anyone can think it through and see what I mean.
No personal knowledge but Hargreaves seem to cover stuff pretty well from wot I've read here.
Starknight posted this link earlier https://accustem.com/investors/ which has new info at the bottom which may help.
I am probably in a similar situation to you but witha different provider. I just sent them the link to review, maybe you should do the same with Halifax.
Thanks, I've been keeping an eye but missed that. It might help me finally monetise these shares and move on!! :-)
I meant pattern, obv...
Are they not already trading? This looks like a trading lattern to me.
https://www.nasdaq.com/market-activity/stocks/acut
20 to1 bull. So you have 650.
How does that help them raise money?
Surely that'll be done by a further share issue?
Bleed the mugs dry... :-)
BB is about right. If you look at the $3 price page there is no history. IMO it's just set up waiting for data to be populated and $3 is the default (and the minimum IIRC)
CREST is UK stocks only isn't it, so I'm not sure they'd have much to comment on...?
There is a contact form on the Accustem website and this email on Tils info@tizianalifesciences.com but I guess you've tried them?
This is the formal US SEC filing (like an RNS) describing the appointment of Wendy Blosser to the post of CEO of Accustem. it includes her salary details ($425,000 pa plus substantial annual bonus and a substantial stock option (490,000 @ exercise price of $2.13) over a defined period. That isn't peanuts. I wonder how they will fund that linger term if there is nothing to sell yet. But it is promising (except they'll probably need to fund raise before too long...)
https://sec.report/Document/0001493152-22-006524/
For any who missed it, the management team was announced a week or so back and details are on the company website at https://accustem.com/about/